Recombinant Production of Hyaluronic Acid

Stephen   H.   Brown; Philip   E.   Pummill

doi:10.2174/138920108785161488

Abstract

Presently, the two main commercial sources of hyaluronic acid (HA) are rooster combs and streptococci. Harvesting from rooster combs is complex and costly. Streptococci are difficult to genetically manipulate and require complex media for growth. Both sources have potential problems with unwanted by-products, such as allergens and toxins. These problems can be solved by producing the HA with safe bacilli that are expressing a recombinant HA synthase (HAS).

Keywords: Hyaluronic Acid, Bacillus subtilis, synthase, fermentation

« Previous Next »

Rights & Permissions Print Cite

Current Pharmaceutical Biotechnology

Title: Recombinant Production of Hyaluronic Acid

Volume: 9 Issue: 4

Author(s): Stephen H. Brown and Philip E. Pummill

Affiliation:

Keywords: Hyaluronic Acid, Bacillus subtilis, synthase, fermentation

Abstract: Presently, the two main commercial sources of hyaluronic acid (HA) are rooster combs and streptococci. Harvesting from rooster combs is complex and costly. Streptococci are difficult to genetically manipulate and require complex media for growth. Both sources have potential problems with unwanted by-products, such as allergens and toxins. These problems can be solved by producing the HA with safe bacilli that are expressing a recombinant HA synthase (HAS).

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Brown H. Stephen and Pummill E. Philip, Recombinant Production of Hyaluronic Acid, Current Pharmaceutical Biotechnology 2008; 9 (4) . https://dx.doi.org/10.2174/138920108785161488

DOI https://dx.doi.org/10.2174/138920108785161488	Print ISSN 1389-2010
Publisher Name Bentham Science Publisher	Online ISSN 1873-4316

About this journal

Call for Papers in Thematic Issues

Submission closes on : 10 April, 2026

25th Anniversary Special Issue.

Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more

Guest Editor(s): Professor Nikolaos Labrou

Submission closes on : 31 December, 2025

Latest Advancements in Biotherapeutics.

The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more

Guest Editor(s): Dr. Satish Rojekar

Submission closes on : 31 December, 2025

Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare

The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more

Guest Editor(s): Dr. Baha Ihnaini

Submission closes on : 28 May, 2026

Process Development of Cell & Gene Therapy.

Cell and Gene Therapy is one of the most fundamental sectors of the biopharmaceutical industry. An efficient process development not only lowers the cost of CMC manufacturing but also best guarantees the quality of the production of biologics for newer Cell and Gene Therapy modalities. Here, we provide the Special ...read more

Guest Editor(s): Dr. Xi-Antonio Ge